|
|
||||||||
Clinical Chemistry, Vol 40, 608-612, Copyright © 1994 by American Association for Clinical Chemistry
RE Wagener, MW Linder and R Valdes Jr
Department of Pathology, University of Louisville School of Medicine, University of Louisville Hospital, KY 40292.
During routine drug analysis with the Syva d.a.u. Emit immunoassays we observed a high frequency of urines with lower rates of changes in absorbance (delta A R) than the rate for a drug-free urine calibrator. Many of these urines contained salicylates. Among 40 urines with apparent salicylate concentrations between 15 and 420 mg/dL tested for benzoylecgonine (BE), 20 had delta A R < -4 (range +2 to -28 mA/min). The rates decreased with increasing salicylate: delta A R = -0.057 x (salicylate, mg/dL) -0.22 mA/min (r = 0.85, n = 40, P < 0.01). Urines from 100 control subjects (no salicylate) had mean +/- SD delta A R values of -1.05 +/- 2.2 mA/min (range +3 to -7; only two were < -4 mA/min). Although direct addition of salicylic acid (200 mg/dL) to urine specimens did not reproduce the negative bias, ingestion of aspirin (acetylsalicylic acid) did by -0.09 mA/min per 1 mg/dL (72.4 mumol/L) salicylate. Negative biases observed for other Emit d.a.u. assays after salicylate ingestion lead us to conclude that ingestion of therapeutic doses of aspirin may cause false-negative results for drug screens in urines by this technology.
The following articles in journals at HighWire Press have cited this article:
![]() |
G. M. Reisfield, E. Salazar, and R. L. Bertholf Rational Use and Interpretation of Urine Drug Testing in Chronic Opioid Therapy Ann. Clin. Lab. Sci., January 1, 2007; 37(4): 301 - 314. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |